We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

INFQ:NYSEInfleqtion, Inc. Analysis

Data as of 2026-06-17 - not real-time

$13.73

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Infleqtion, Inc. (INFQ) has entered a pivotal phase, with its recent UK Quantum Innovation Centre launch boosting market enthusiasm and driving the stock higher. Technically, the price sits above the 200‑day SMA but below the 20‑day and 50‑day SMAs, while the RSI hovers near the midpoint, suggesting limited upside momentum. The MACD histogram remains negative, flagging bearish short‑term pressure, and volume trends are declining, tempering the rally. However, the company’s cash balance of over $400 million dwarfs its modest $33 million revenue base, providing a substantial liquidity cushion despite negative operating cash flow and a recent max drawdown of more than 40 percent. The extreme beta of nearly five and a 30‑day volatility above 150 percent underline a high‑risk, high‑reward profile. Coupled with news of a 100‑qubit quantum computer delivery and a new ETF targeting INFQ, the narrative is strongly growth‑oriented, though fundamentals remain weak.
Investors should weigh the bullish sentiment from strategic partnerships and government‑backed expansion against the overvalued pricing metrics—price‑to‑sales near 90 and price‑to‑book above five—while recognizing the speculative nature of the quantum‑technology sector.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram and declining volume
  • Recent price rally driven by news rather than fundamentals
  • High short‑term volatility and beta

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic UK expansion and first 100‑qubit delivery
  • Strong cash position supporting R&D and scale‑up
  • Potential upside of over 50 percent based on upside/downside estimate

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Quantum‑technology market still nascent with execution risk
  • Continued earnings losses and negative cash flow
  • Valuation remains stretched relative to revenue and book value

Key Metrics & Analysis

Financial Health

Revenue Growth13.90%
Profit Margin-166.77%
P/E Ratio-91.1
Debt/Equity0.84
P/B Ratio5.1
Op. Cash Flow$-36332000
Industry P/E37.7

Technical Analysis

TrendBullish
RSI47.4
Support$10.45
Resistance$20.75
MA 20$15.28
MA 50$14.03
MA 200$12.88
MACDBearish
VolumeDecreasing
Fear & Greed Index91.3

Valuation

Target Price$21.00
Upside/Downside52.95%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta5.00
Volatility152.95%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.